Inhibitory effect of Chunghyuldan in prostaglandin E2 and nitric oxide biosynthesis of lipopolysaccharide-induced RAW 264.7 cells

Biological and Pharmaceutical Bulletin

Volumn 27, Issue 11, 2004, Pages 1810-1813

  Cho, Ki Ho ^a   Kim, Young Suk ^a   Bae, Hyung Sup ^a   Moon, Sang Kwan ^a   Jung, Woo Sang ^a   Park, Eun Kyung ^a   Kim, Dong Hyun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Chunghyuldan; Cyclooxygenase (COX) 2; Daio Orengedokuto; Ischemia; Nitric oxide; Prostaglandin E2

Indexed keywords

ANTIINFLAMMATORY AGENT; CHUNGHYULDAN; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; NITRIC OXIDE; PROSTAGLANDIN E2; UNCLASSIFIED DRUG; ANTIOXIDANT; HERBACEOUS AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; NOS2 PROTEIN, MOUSE; PROSTAGLANDIN SYNTHASE; SCAVENGER;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; MOUSE; NONHUMAN; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; ANIMAL; BIOSYNTHESIS; CELL LINE; DRUG ANTAGONISM; METABOLISM; WESTERN BLOTTING;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIOXIDANTS; BLOTTING, WESTERN; CELL LINE; CYCLOOXYGENASE 2; DINOPROSTONE; DRUGS, CHINESE HERBAL; FREE RADICAL SCAVENGERS; LIPOPOLYSACCHARIDES; MICE; NF-KAPPA B; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 21144439044     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.27.1810     Document Type: Article

References (16)

1. Barber P. A., Demchuk A. M., Hirt L., Buchan A. M., Adv. Neurol., 92, 151-164 (2003).
2. Bartosik-Psujek H., Belniak E., Stelmasiak Z., Neurol. Sci., 24, 279-280 (2003).
3. Appleton I., Tomlinsom A., Willoughby D. A., Adv. Pharmacol., 35, 27-78 (1996).
4. Stefanovic-Racic S., Stadler J., Evans C. H., Arthritis Rheum., 36, 1036-1044 (1993).
5. MacMicking J. D., Xie Q. W., Nathan C., Ann. Rev. Immunol., 15, 323-350 (1997).
6. Smith W. L., Garavito R. M., DeWitt D. L., J. Biol. Chem., 271, 33157-33160 (1996).
7. Dubois R. N., Abramson S. B., Crofford L., Gupta R. A., Simon L. S., Van De Putte L. B. A., Lipsky P. E., FASEB J., 12, 1063-1073 (1998).
8. Perkins D. J., Kniss D. A., J. Leukoc. Biol., 65, 792-799 (1999).
9. Kim Y. S., Jung E. A., Shin J. E., Chang J. C., Yang H. K., Kim N. J., Cho K. H., Kim D.-H., Biol. Pharm. Bull., 25, 1442-1445 (2002).
10. Yang H. K., Kim Y. S., Bae H. S., Cho K. H., Shin J. E., Kim N. J., Kim D.-H., Nat. Prod. Sci., 9, 38-43 (2003).
11. Jung W. S., Am. J. Chin. Med., in press (2004).
12. Xiong Q., Kadota S., Tani T., Namba T., Chem. Pharm. Bull., 19, 1580-1585 (1996).
13. Choi O. H., Kim J. H., Kinet J. P., Nature (London), 380, 634-636 (1996).
14. Ishihara T., Kohno K., Ushio S., Iwaki K., Ikeda M., Kurimoto M., Eur. J. Pharmacol., 407, 197-204 (2000).
15. Kim D.-H., Nat. Prod. Sci., 8, 35-43 (2002).
16. Kobashi K., Akao T., Bifidobacteria Microflora, 16, 1-7 (1997).